Skip to Content

Bellicum Pharmaceuticals Inc - Stock Quote BLCM

Rating as of

Morningstar's Bellicum Pharmaceuticals Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Bellicum Pharmaceuticals Inc's Company Profile

Business Description

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.

3730 Kirby Drive, Suite 1200
Houston, TX, 77098
T +1 281 454-3424
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Speculative Growth
Employees 7